Screener
BioMarin Pharmaceuticals BMRN Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's finite lived intangible assets - gross?
- BioMarin Pharmaceuticals (BMRN) reported finite lived intangible assets - gross of $5.17B in Q2 2026.
- How has BioMarin Pharmaceuticals's finite lived intangible assets - gross changed year-over-year?
- BioMarin Pharmaceuticals's finite lived intangible assets - gross increased by 617.2% year-over-year, from $721.32M to $5.17B.
- What is the long-term trend for BioMarin Pharmaceuticals's finite lived intangible assets - gross?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's finite lived intangible assets - gross has grown at a 2.4% compound annual growth rate (CAGR), from $644.09M to $723.97M.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.
Ask your AI about BioMarin Pharmaceuticals's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude